Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in <i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

<table>Mean SICT domain scores at baseline and EOS for MDS population with prior history of ICT.</table>

Anemia

fig4

Figure 4

Figure 4: Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in <i>β</i>-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial 

Figure 4 | Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial 